Marisa Wexler, MS,  senior science writer—

ARINA-1, a nebulized therapy being developed by Renovion for cystic fibrosis (CF) and other chronic inflammatory lung diseases, may be better than currently available options for clearing mucus in CF patients with the most common CFTR mutation, results of a study in cell models of CF showed. The…

Rage Biotech, a new company building on research done at leading Australian universities, aims to develop treatments to help people with chronic inflammatory lung diseases, including cystic fibrosis, severe asthma, and chronic obstructive pulmonary disease. Supported by investments from the IP Group, Monash University, and…

NHS England and Vertex Pharmaceuticals have reached an agreement that will allow access to Vertex’s Kaftrio (ivacaftor/tezacaftor/elexacaftor), a triple combination therapy for cystic fibrosis (CF) to be used in a combination regimen with Kalydeco, as soon as the medication is approved by the European…

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor) as a treatment for cystic fibrosis (CF) in people 12 and older who have either two F508del mutations or one F508del mutation and…

Nontuberculous mycobacteria (NTM), a type of infectious bacteria, is able to survive being dried for a full day, a study found, suggesting that drying is not a sufficient way to disinfect nebulizers used by people with cystic fibrosis (CF). The study, “Susceptibility of the Mycobacterium…

Most people in the U.K. are unaware of the challenges faced by people living with cystic fibrosis (CF), according to results of a YouGov poll commissioned by the U.K. Cystic Fibrosis Trust. Data from the survey indicates that four of five people in the general public do not…

The third annual CF FamilyCon, a free and online event that connects people with cystic fibrosis (CF) and their extended families and friends with one another — and to others — takes place this weekend. This two-day event, supported by the Cystic Fibrosis Foundation, is set for…

During COVID-19, the U.K. Cystic Fibrosis Registry is taking steps to further the collection of data on how the ongoing pandemic is affecting people with cystic fibrosis (CF). The CF Registry, managed by the Cystic Fibrosis Trust, records data on patients in England, Wales, Scotland, and Northern…

A potential gene therapy for cystic fibrosis, KB407, is able to induce the expression of normal CFTR protein in cell models of CF, its developer, Krystal Biotech, reports. These data are in the poster, “In vitro Pharmacology of KB407, an HSV-1 based gene therapy vector,…

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for a label extension of the cystic fibrosis (CF) treatment Kalydeco (ivacaftor). If approved by the European Commission, the extension would allow Kalydeco use in patients 6…